Canaan Partners

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Archipelago Analytics, Inc., based in San Francisco, California, was incorporated in 2018 and specializes in utilizing artificial intelligence to enhance risk management for large commercial property owners. The company's platform digitizes risk data, facilitating improved insurance outcomes and overall resilience. By enabling the efficient movement of critical information through the insurance value chain—from clients to brokers and capacity providers—Archipelago aims to lower the total cost of risk for its users, ensuring they receive timely and relevant data to make informed decisions.

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Leanplum Inc. is a mobile marketing platform that specializes in enhancing engagement for brands through a unified, multichannel approach. Founded in 2012 and headquartered in San Francisco, with additional offices in New York, London, Bulgaria, and Amsterdam, Leanplum enables businesses to optimize their mobile applications and marketing efforts. The platform offers a range of services including messaging, automation, app editing, personalization, A/B testing, and analytics, allowing product teams to conduct real-time optimization tests and analyze results effectively. Renowned global brands such as Tinder, Grab, Tesco, and Zynga utilize Leanplum to orchestrate integrated campaigns that foster customer loyalty and drive growth. By transforming data into actionable insights, Leanplum helps companies understand user needs, delivering relevant experiences that enhance brand engagement and establish long-term customer relationships.

Archipelago Analytics, Inc., based in San Francisco, California, was incorporated in 2018 and specializes in utilizing artificial intelligence to enhance risk management for large commercial property owners. The company's platform digitizes risk data, facilitating improved insurance outcomes and overall resilience. By enabling the efficient movement of critical information through the insurance value chain—from clients to brokers and capacity providers—Archipelago aims to lower the total cost of risk for its users, ensuring they receive timely and relevant data to make informed decisions.

Founded in 1985, Commonwealth Labs operates a specialized diagnostic laboratory based in San Francisco. It offers advanced tests for functional gastrointestinal disorders, serving healthcare providers.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Leanplum Inc. is a mobile marketing platform that specializes in enhancing engagement for brands through a unified, multichannel approach. Founded in 2012 and headquartered in San Francisco, with additional offices in New York, London, Bulgaria, and Amsterdam, Leanplum enables businesses to optimize their mobile applications and marketing efforts. The platform offers a range of services including messaging, automation, app editing, personalization, A/B testing, and analytics, allowing product teams to conduct real-time optimization tests and analyze results effectively. Renowned global brands such as Tinder, Grab, Tesco, and Zynga utilize Leanplum to orchestrate integrated campaigns that foster customer loyalty and drive growth. By transforming data into actionable insights, Leanplum helps companies understand user needs, delivering relevant experiences that enhance brand engagement and establish long-term customer relationships.

Ascendify Corporation specializes in developing innovative talent management solutions that transform how companies attract, develop, and retain employees. The company's flagship product, the Intelligent People Management platform, utilizes machine learning and predictive analytics to streamline recruiting and talent development processes. This cloud-based platform enables organizations to effectively identify and connect with potential candidates while also assessing their skills and training needs. Headquartered in San Francisco, Ascendify serves a diverse clientele, including prominent corporations such as GE, Cisco, Panasonic, Disney, Deloitte, and Marriott, reinforcing its position as a key player in the talent acquisition software industry.

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Beam Solutions is a venture-backed regulatory technology (regtech) software company based in the San Francisco Bay Area. It specializes in developing an anti-money laundering platform that addresses compliance challenges faced by financial institutions. Beam's proprietary transaction monitoring technologies utilize advanced machine learning and innovative data sources to significantly reduce false positives and enhance the detection of suspicious activities. This end-to-end compliance solution not only improves efficiency but also helps banks, credit unions, and fintech companies navigate the complexities of regulatory requirements. By employing a transparent-box approach, Beam elucidates its machine learning processes, ensuring clarity for regulators and bolstering their understanding and approval. The company is supported by a knowledgeable team of officers, directors, advisors, and investors.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Cardlytics operates an advertising platform within financial institutions' digital channels, enabling marketers to reach consumers through trusted online and mobile banking channels. It uses purchase-based intelligence to make marketing more relevant and measurable, partnering with over 1,500 financial institutions worldwide.

Leanplum Inc. is a mobile marketing platform that specializes in enhancing engagement for brands through a unified, multichannel approach. Founded in 2012 and headquartered in San Francisco, with additional offices in New York, London, Bulgaria, and Amsterdam, Leanplum enables businesses to optimize their mobile applications and marketing efforts. The platform offers a range of services including messaging, automation, app editing, personalization, A/B testing, and analytics, allowing product teams to conduct real-time optimization tests and analyze results effectively. Renowned global brands such as Tinder, Grab, Tesco, and Zynga utilize Leanplum to orchestrate integrated campaigns that foster customer loyalty and drive growth. By transforming data into actionable insights, Leanplum helps companies understand user needs, delivering relevant experiences that enhance brand engagement and establish long-term customer relationships.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company that develops proteolytically-activated antibodies based on its Probody technology platform. Probody therapeutics are designed to be activated by the tumor microenvironment, enabling targeted cancer immunotherapies with reduced activity in healthy tissues. The company advances antibody and antibody-drug conjugate programs such as CX-072 (PD-L1), CX-2009 (CD166-targeted PDC), BMS-986249 (CTLA-4 Probody), CX-2029 (CD71-targeted PDC), and BMS-986288 (CTLA-4 Probody) in clinical research, and maintains collaborations with AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas to develop Probody therapeutics. Founded in 2008 and headquartered in South San Francisco, the company aims to improve the precision and safety of antibody-based therapies for cancer and inflammatory diseases.

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Cuyana, Inc. is a San Francisco-based fashion brand that focuses on manufacturing and retailing high-quality clothing, bodysuits, bags, small leather goods, and accessories. Founded in 2011, the company promotes the philosophy of "fewer, better things," offering timeless pieces designed with a modern aesthetic and crafted from premium materials to ensure durability. Cuyana operates an online platform for direct-to-consumer sales, allowing it to provide luxury-quality products at attainable prices. In addition to its online presence, Cuyana has physical showrooms in locations such as Palo Alto, New York City, Pacific Palisades, and Venice. Through its unique approach, Cuyana aims to bridge the gap between luxury and affordability in the fashion industry.

Near Pte. Ltd., also known as AdNear, operates a location-based intelligence platform that delivers real-time insights about places, people, and products. Founded in 2012 and headquartered in Singapore, the company specializes in data-driven solutions that help brands and publishers engage and analyze audiences. Its offerings include Allspark, a mobile-first audience cloud solution, and Carbon, which analyzes real-world consumer behavior across significant locations. Near's platform processes data from approximately 1.6 billion unique user IDs and 70 million points of interest across over 44 countries, enabling clients to better understand consumer behaviors and preferences. The company serves a diverse range of industries, including retail, technology, travel, telecommunications, and financial services, with additional offices in major global cities such as San Francisco, New York, London, Bengaluru, Tokyo, and Sydney.

Koolbit is a high-growth mobile and social casino game company known for having the largest portfolio of mobile games globally. Founded in Silicon Valley by Gerard Cunningham, an experienced figure in the iGaming industry, Koolbit focuses on developing a gaming platform that delivers mobile and social casino content across various social networks and mobile operating systems. Its platform features real-time reporting, player notifications, remote updates, and performance tuning, all designed to enhance the gaming experience for users. By combining innovative technology with a vast selection of games, Koolbit aims to provide an engaging and endless gaming experience.

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company that develops proteolytically-activated antibodies based on its Probody technology platform. Probody therapeutics are designed to be activated by the tumor microenvironment, enabling targeted cancer immunotherapies with reduced activity in healthy tissues. The company advances antibody and antibody-drug conjugate programs such as CX-072 (PD-L1), CX-2009 (CD166-targeted PDC), BMS-986249 (CTLA-4 Probody), CX-2029 (CD71-targeted PDC), and BMS-986288 (CTLA-4 Probody) in clinical research, and maintains collaborations with AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas to develop Probody therapeutics. Founded in 2008 and headquartered in South San Francisco, the company aims to improve the precision and safety of antibody-based therapies for cancer and inflammatory diseases.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Cardlytics operates an advertising platform within financial institutions' digital channels, enabling marketers to reach consumers through trusted online and mobile banking channels. It uses purchase-based intelligence to make marketing more relevant and measurable, partnering with over 1,500 financial institutions worldwide.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Blurb, Inc. operates a self-publishing and marketing platform that allows users to create and publish a variety of books and magazines in both print and digital formats. Founded in 2005 and headquartered in San Francisco with an additional office in London, the company offers tools such as an Adobe InDesign plug-in and BookWright, enabling users to design and layout books, photo books, and magazines. Blurb caters to a diverse range of publishing needs, including trade books, photography, memoirs, and personalized keepsakes. Authors can utilize Blurb's platform to sell their works directly through their own websites or social media, with the company managing the printing and shipping of orders. Blurb is recognized for its focus on high-quality coffee table books and fixed-format ebooks, making it a popular choice for both professional and amateur creators. As of August 2020, Blurb operates as a subsidiary of Reischling Press, Inc.

Blurb, Inc. operates a self-publishing and marketing platform that allows users to create and publish a variety of books and magazines in both print and digital formats. Founded in 2005 and headquartered in San Francisco with an additional office in London, the company offers tools such as an Adobe InDesign plug-in and BookWright, enabling users to design and layout books, photo books, and magazines. Blurb caters to a diverse range of publishing needs, including trade books, photography, memoirs, and personalized keepsakes. Authors can utilize Blurb's platform to sell their works directly through their own websites or social media, with the company managing the printing and shipping of orders. Blurb is recognized for its focus on high-quality coffee table books and fixed-format ebooks, making it a popular choice for both professional and amateur creators. As of August 2020, Blurb operates as a subsidiary of Reischling Press, Inc.

Blurb, Inc. operates a self-publishing and marketing platform that allows users to create and publish a variety of books and magazines in both print and digital formats. Founded in 2005 and headquartered in San Francisco with an additional office in London, the company offers tools such as an Adobe InDesign plug-in and BookWright, enabling users to design and layout books, photo books, and magazines. Blurb caters to a diverse range of publishing needs, including trade books, photography, memoirs, and personalized keepsakes. Authors can utilize Blurb's platform to sell their works directly through their own websites or social media, with the company managing the printing and shipping of orders. Blurb is recognized for its focus on high-quality coffee table books and fixed-format ebooks, making it a popular choice for both professional and amateur creators. As of August 2020, Blurb operates as a subsidiary of Reischling Press, Inc.

Located in San Francisco's SOMA district, User Interface, Inc. offers B2B companies the technology and the strategies necessary to forge stronger company-customer relationships. User Interface clients, including Cisco Systems, Digital Island, Commerce One and Informatica, rely on the company for assistance with gathering and leveraging contextual intelligence on customers. To increase customer satisfaction and retention, companies need to understand their customers. Working with major B2B technology companies, User Interface has developed detailed methodologies for gathering, analyzing, and distributing customer intelligence. Underlying those methodologies is the Customer Intelligence System (CIS), which offers their clients easy access to post-sales customer information.